XKRX
293780
Market cap174mUSD
Jul 11, Last price
8,960.00KRW
1D
0.45%
1Q
19.79%
IPO
-77.82%
Name
AptaBio Therapeutics Inc
Chart & Performance
Profile
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY |
---|---|---|
2024‑12 | 2023‑12 | |
Income | ||
Revenues | 3,360,980 937.76% | 323,869 |
Cost of revenue | 19,314,473 | 14,141,453 |
Unusual Expense (Income) | ||
NOPBT | (15,953,493) | (13,817,584) |
NOPBT Margin | ||
Operating Taxes | 1,575,110 | (2,630,201) |
Tax Rate | ||
NOPAT | (17,528,603) | (11,187,383) |
Net income | (29,377,950) 143.57% | (12,061,644) |
Dividends | ||
Dividend yield | ||
Proceeds from repurchase of equity | (6,087) | |
BB yield | ||
Debt | ||
Debt current | 7,398,995 | 131,075 |
Long-term debt | 398,613 | 14,167,422 |
Deferred revenue | ||
Other long-term liabilities | 3,574,630 | 16,534,873 |
Net debt | (48,923,658) | (68,239,463) |
Cash flow | ||
Cash from operating activities | (12,159,710) | (14,095,171) |
CAPEX | (240,162) | (167,391) |
Cash from investing activities | 12,853,535 | (12,737,197) |
Cash from financing activities | (167,306) | 49,854,461 |
FCF | (13,830,801) | |
Balance | ||
Cash | 31,515,054 | 52,885,298 |
Long term investments | 25,206,213 | 29,652,662 |
Excess cash | 56,553,217 | 82,521,766 |
Stockholders' equity | (96,671,314) | (68,348,604) |
Invested Capital | 161,964,009 | 160,180,843 |
ROIC | ||
ROCE | ||
EV | ||
Common stock shares outstanding | 23,065 | 22,299 |
Price | ||
Market cap | ||
EV | ||
EBITDA | (15,422,139) | (13,278,475) |
EV/EBITDA | ||
Interest | 3,401,095 | 1,182,961 |
Interest/NOPBT |